Moreover, an exploratory cohort of 60 patients showed that soluble LFA-3 expressed at the cell surface of CLL cells correlated with increased overall survival after frontline rituximab-based immunochemotherapy. This evidence concerns the gene CD58 and B-cell chronic lymphocytic leukemia.